Insider filing · BNTC

Suvretta Capital Management, Llc bought $20.0M of Benitec Biopharma (BNTC)

Executed Nov 7 2025, disclosed Nov 11 2025, 3 days later.

Over the 21 trading sessions from the disclosed entry session (Nov 10 2025), the stock returned -1.3% (delay-adjusted); from the execution session (Nov 7 2025), +11.1%. Derived: entry at the session's open, exit at the close 20 sessions later.

SL Suvretta Capital Management, Llc Director profile →

Suvretta Capital Management, Llc (Director) filed 4 Form 4 reports as a reporting entity in the trailing twelve months (4 purchases, 0 sales, 2 filed past the two-business-day deadline), most often in BNTC. Across 4 priced purchase filings, the average 21-session return was +15.0% from execution and +9.0% from disclosure (delay-adjusted; derived). The largest single filing was $20.0M of BNTC (1,481,481 sh across 2 lots, as filed), executed Nov 7 2025.

BNTC BNTC BNTC · 8 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→